

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Olaparib in combination with bevacizumab for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy with bevacizumab ID1652

Stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • AstraZeneca (olaparib) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Black Health Agency • Cancer Black Care • Cancer Equality • Cancer 52 • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Macmillan Cancer Support • Maggie's Centres • Marie Curie • Muslim Council of Britain • Ovacome • Ovarian Cancer Action • South Asian Health Foundation • Specialised Healthcare Alliance • Target Ovarian Cancer • Tenovus Cancer Care • Wellbeing of Women • The Eve Appeal • The Robin Cancer Trust • Women's Health Concern <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • British Geriatrics Society • British Gynaecological Cancer Society • British Institute of Radiology • British Psychosocial Oncology Society • British Society of Urogynaecology • Cancer Research UK • National Forum of Gynaecological 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • All Wales Therapeutics and Toxicology Centre • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Roche (bevacizumab) • Pfizer (bevacizumab) • Amgen (bevacizumab) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Gynaecological Cancer Group • Genomics England • Institute of Cancer Research • MRC Clinical Trials Unit • National Cancer Research Institute • National Cancer Research Network

Stakeholder list for the technology appraisal of olaparib in combination with bevacizumab for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy with bevacizumab ID1652. Issue date: January 2020

Consultees	Commentators (no right to submit or appeal)
<p>Oncology Nurses</p> <ul style="list-style-type: none"> • Royal College of General Practitioners • Royal College of Nursing • Royal College of Obstetricians & Gynaecologists • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • UK Clinical Pharmacy Association • UK Health Forum • UK Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS Bath and North East Somerset CCG • NHS England • NHS Wiltshire CCG • Welsh Government 	<ul style="list-style-type: none"> • National Institute for Health Research • Ovarian & Prostate Cancer Research Trust <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTTEES AND COMMENTATORS

Definitions:

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.